Atea Pharmaceuticals (AVIR) announced the presentation of new modeling data predicting that the Company’s combination regimen of bemnifosbuvir, ...

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3 rd-generation EGFR inhibitors and outperforms other investigational 4 th-generation inhibitors ...